Cargando…
Is Memantine Effective as an NMDA Receptor Antagonist in Adjunctive Therapy for Schizophrenia?
Memantine, an N-methyl-d-aspartate (NMDA) receptor antagonist approved for treating Alzheimer’s disease, has a good safety profile and is increasingly being studied for possible use in a variety of non-dementia psychiatric disorders. There is an abundance of basic and clinical data that support the...
Autor principal: | Kikuchi, Tetsuro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466074/ https://www.ncbi.nlm.nih.gov/pubmed/32751985 http://dx.doi.org/10.3390/biom10081134 |
Ejemplares similares
-
The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi
por: Santos Souza, Higo Fernando, et al.
Publicado: (2019) -
Effects of Memantine, an NMDA Antagonist, on Metabolic Syndromes in Female NMRI Mice
por: Osanloo, Naser, et al.
Publicado: (2015) -
Computational Modeling of Therapy with the NMDA Antagonist in Neurodegenerative Disease: Information Theory in the Mechanism of Action of Memantine
por: Świetlik, Dariusz, et al.
Publicado: (2022) -
Virtual Therapy with the NMDA Antagonist Memantine in Hippocampal Models of Moderate to Severe Alzheimer’s Disease, In Silico Trials
por: Świetlik, Dariusz, et al.
Publicado: (2022) -
Adjunctive Memantine Therapy for Cognitive Impairment in Chronic Schizophrenia: A Placebo-Controlled Pilot Study
por: Lee, Jung Goo, et al.
Publicado: (2012)